Perioperative Gabapentin Improves Patient-Centered Outcomes After Inguinal Hernia Repair

Mil Med. 2017 Nov;182(11):e2052-e2055. doi: 10.7205/MILMED-D-17-00107.

Abstract

Introduction: Over 5,300 inguinal hernia repairs (IHR) were performed in the Military Health System in 2015. Chronic pain can be a debilitating complication, occurring in up to 34% of patients after IHR and impacts mission readiness. Gabapentin has been shown to be effective for postoperative analgesia in a variety of operations. We evaluated the effect of a short course of perioperative gabapentin on chronic pain after IHR.

Methods: This was a double-blinded, randomized study involving male patients ≥18 years old with an initial inguinal hernia and no history of chronic pain or psychiatric disorder. Patients chose laparoscopic or open surgery and were then randomized to receive gabapentin 300 mg before surgery, then three times daily for 6 doses or placebo. There were 50 patients randomized to both the gabapentin and placebo groups for a total of 100 patients. Main outcomes were pain and health status, assessed with a visual analogue scale (VAS) and the Short Form-12v2 (SF-12v2). Assessments were performed preoperatively and 1, 6, 12, and 24 months postoperatively. Analysis of variance was used to compare groups.

Results: From the initial 100 patients, 19 withdrew or were excluded. Thus, 81 patients remained, 40 receiving gabapentin and 41 placebo. Throughout the 24-month follow-up, there was no difference in VAS pain scores between the gabapentin and placebo groups (p = 0.867). Beyond 1 month of follow-up, SF-12v2 physical component score (PCS) scores were improved in the gabapentin group (p = 0.039). When comparing open to laparoscopic groups, SF-12v2 PCS scores were improved in the laparoscopic group (p = 0.046) and SF-12v2 mental component summary scores were improved in the open group (p = 0.041).

Conclusions: Perioperative gabapentin was not effective in decreasing chronic pain after IHR; however, patient perception of physical health, as measured by SF-12v2, did improve.

Trial registration: ClinicalTrials.gov NCT02419443.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adjuvants, Anesthesia / pharmacology
  • Adjuvants, Anesthesia / therapeutic use
  • Adult
  • Amines / pharmacology*
  • Amines / therapeutic use
  • Androstanols / pharmacology
  • Androstanols / therapeutic use
  • Anesthetics, Local / pharmacology
  • Anesthetics, Local / therapeutic use
  • Antiemetics / pharmacology
  • Antiemetics / therapeutic use
  • Calcium Channel Blockers / therapeutic use
  • Cyclohexanecarboxylic Acids / pharmacology*
  • Cyclohexanecarboxylic Acids / therapeutic use
  • Double-Blind Method
  • Female
  • Fentanyl / pharmacology
  • Fentanyl / therapeutic use
  • Gabapentin
  • Hernia, Inguinal / drug therapy*
  • Hernia, Inguinal / surgery
  • Humans
  • Hypnotics and Sedatives / pharmacology
  • Hypnotics and Sedatives / therapeutic use
  • Lidocaine / pharmacology
  • Lidocaine / therapeutic use
  • Male
  • Midazolam / pharmacology
  • Midazolam / therapeutic use
  • Middle Aged
  • Neuromuscular Depolarizing Agents / pharmacology
  • Neuromuscular Depolarizing Agents / therapeutic use
  • Ondansetron / pharmacology
  • Ondansetron / therapeutic use
  • Placebos / therapeutic use
  • Plastic Surgery Procedures / methods*
  • Propofol / pharmacology
  • Propofol / therapeutic use
  • Quality of Life / psychology*
  • Rocuronium
  • Succinylcholine / pharmacology
  • Succinylcholine / therapeutic use
  • Treatment Outcome*
  • gamma-Aminobutyric Acid / pharmacology*
  • gamma-Aminobutyric Acid / therapeutic use

Substances

  • Adjuvants, Anesthesia
  • Amines
  • Androstanols
  • Anesthetics, Local
  • Antiemetics
  • Calcium Channel Blockers
  • Cyclohexanecarboxylic Acids
  • Hypnotics and Sedatives
  • Neuromuscular Depolarizing Agents
  • Placebos
  • Ondansetron
  • gamma-Aminobutyric Acid
  • Gabapentin
  • Lidocaine
  • Succinylcholine
  • Midazolam
  • Fentanyl
  • Rocuronium
  • Propofol

Associated data

  • ClinicalTrials.gov/NCT02419443